Keywords: dor/dowpharma, sign, development, deal, botulinum, vacc, dor

DOR/Dowpharma sign development deal for botulinum vacc

Article | 08 August 2005

Print This

DOR BioPharma has entered into a joint development agreement with fellow USA-based group Dowpharma, a business unit of Dow Chemical, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in